Wedbush upgraded shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) from a neutral rating to an outperform rating in a research report report published on Tuesday. They currently have $42.00 price objective on the biopharmaceutical company’s stock.

Other equities research analysts also recently issued reports about the stock. Vetr raised shares of Juno Therapeutics to a buy rating in a report on Tuesday, May 23rd. BidaskClub raised shares of Juno Therapeutics from a hold rating to a buy rating in a report on Tuesday, June 20th. Zacks Investment Research downgraded shares of Juno Therapeutics from a buy rating to a hold rating in a report on Tuesday, May 2nd. BTIG Research downgraded shares of Juno Therapeutics from a neutral rating to a sell rating and increased their price target for the stock from $12.00 to $23.00 in a report on Tuesday, June 6th. Finally, FBR & Co reissued a hold rating on shares of Juno Therapeutics in a report on Thursday, May 18th. Two analysts have rated the stock with a sell rating, six have given a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average target price of $31.86.

Shares of Juno Therapeutics (JUNO) opened at 43.81 on Tuesday. Juno Therapeutics has a 1-year low of $17.52 and a 1-year high of $44.60. The company’s market cap is $4.60 billion. The company has a 50-day moving average of $28.62 and a 200-day moving average of $25.14. Juno Therapeutics also was the recipient of unusually large options trading activity on Tuesday. Investors purchased 6,838 put options on the company. This is an increase of 977% compared to the average volume of 635 put options.

Juno Therapeutics (NASDAQ:JUNO) last announced its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by $0.24. Juno Therapeutics had a negative return on equity of 27.10% and a negative net margin of 354.36%. The firm had revenue of $21.30 million during the quarter, compared to analysts’ expectations of $15.59 million. During the same period in the previous year, the company posted ($0.64) earnings per share. The company’s quarterly revenue was down 22.8% compared to the same quarter last year. Equities analysts forecast that Juno Therapeutics will post ($3.12) EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Juno Therapeutics, Inc. (JUNO) Upgraded to “Outperform” at Wedbush” was reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.watchlistnews.com/juno-therapeutics-inc-juno-upgraded-to-outperform-at-wedbush/1531457.html.

In other Juno Therapeutics news, Director Anthony B. Evnin purchased 9,000 shares of Juno Therapeutics stock in a transaction on Tuesday, June 20th. The shares were acquired at an average cost of $24.40 per share, for a total transaction of $219,600.00. Following the completion of the transaction, the director now directly owns 66,301 shares of the company’s stock, valued at $1,617,744.40. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, Director Richard Klausner sold 12,000 shares of the stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $30.34, for a total transaction of $364,080.00. Following the transaction, the director now owns 788,985 shares in the company, valued at $23,937,804.90. The disclosure for this sale can be found here. Insiders have sold 8,053,500 shares of company stock worth $217,594,440 over the last quarter. Company insiders own 15.26% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Teachers Advisors LLC boosted its position in shares of Juno Therapeutics by 12.3% in the fourth quarter. Teachers Advisors LLC now owns 60,834 shares of the biopharmaceutical company’s stock worth $1,147,000 after buying an additional 6,643 shares during the last quarter. Nisa Investment Advisors LLC acquired a new position in shares of Juno Therapeutics during the first quarter worth approximately $200,000. Wells Fargo & Company MN boosted its position in shares of Juno Therapeutics by 238.4% in the first quarter. Wells Fargo & Company MN now owns 121,392 shares of the biopharmaceutical company’s stock worth $2,693,000 after buying an additional 85,516 shares during the last quarter. Canada Pension Plan Investment Board boosted its position in shares of Juno Therapeutics by 111.2% in the first quarter. Canada Pension Plan Investment Board now owns 94,400 shares of the biopharmaceutical company’s stock worth $2,095,000 after buying an additional 49,700 shares during the last quarter. Finally, Great West Life Assurance Co. Can boosted its position in shares of Juno Therapeutics by 80.5% in the first quarter. Great West Life Assurance Co. Can now owns 8,518 shares of the biopharmaceutical company’s stock worth $189,000 after buying an additional 3,800 shares during the last quarter. Institutional investors and hedge funds own 70.76% of the company’s stock.

About Juno Therapeutics

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Analyst Recommendations for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.